Bloomberg News

Vertex Shares Fall on Little-Changed Incivek Sales

October 17, 2011

Oct. 17 (Bloomberg) -- Vertex Pharmaceuticals Inc., seller of the hepatitis C drug Incivek, fell 3 percent after sales of the medicine were little changed.

Vertex, based in Cambridge, Massachusetts, dropped to $41.98 at 9:39 a.m. New York time. IMS Health Inc., a prescription-data company, said sales of Incivek in the first week of October were “relatively flat over September,” Jason Kantor, an analyst at RBC Capital Markets wrote in a note.

To contact the reporter on this story: Anna Edney in Washington at

To contact the editor responsible for this story: Bruce Rule at

Too Cool for Crisis Management
blog comments powered by Disqus